BioCentury
ARTICLE | Clinical News

AN2898: Phase I data

March 16, 2009 7:00 AM UTC

In a vehicle-controlled, German Phase I trial in 20 healthy volunteers, AN2898 5% ointment applied daily to the skin under occlusive, adhesive patches for 4 consecutive days was well tolerated and dem...